VALENCIA, Calif.--(BUSINESS WIRE)--Today at the International Neuromodulation Society 12th World Congress, Bioness, Inc. announced the commercial availability of StimRouter, an implantable neuromodulation device to treat chronic, intractable pain of peripheral nerve origin as an adjunct to other modes of therapy (e.g., medications). StimRouter received clearance from the United States Food and Drug Administration (FDA) in February and is the only implantable neuromodulation device indicated to treat chronic pain of peripheral nerve origin.
“The commercial launch of StimRouter for peripheral pain positions Bioness to strategically build on the success of our neuromodulation portfolio. In addition to pain applications, we started a pilot study for overactive bladder in February and we anticipate expanding to other commercial markets in the future.”
Bioness President and CEO Todd Cushman commented, “The commercial launch of StimRouter for peripheral pain positions Bioness to strategically build on the success of our neuromodulation portfolio. In addition to pain applications, we started a pilot study for overactive bladder in February and we anticipate expanding to other commercial markets in the future.”
With an estimated 50 million people suffering from chronic pain, contributing an additional $150 billion in annual costs to the U.S. healthcare system, there’s never been a greater need for innovative pain management options. As a minimally invasive device designed to reduce pain by specifically targeting the affected peripheral nerve, StimRouter is a cost-effective alternative to injections, ongoing medication regiments and complex surgeries.
About StimRouter™ Neuromodulation System
StimRouter is cleared by the FDA to treat chronic pain of peripheral nerve origin. StimRouter is a minimally invasive neuromodulation medical device consisting of an implanted lead, external pulse transmitter (EPT) and conductive electrode, controlled by a small, hand-held wireless control unit. Electrical signals are transmitted transdermally from the EPT through the electrode, down the lead to the target nerve. Each system is programmed at the direction of the physician to meet patient requirements.
About Bioness Inc.
Bioness is the leading provider of innovative technologies helping people regain mobility and independence. Bioness solutions include external and implantable functional electrical stimulation (FES) systems, robotic systems and software-based therapy programs providing functional and therapeutic benefits for individuals affected by pain, central nervous system disorders and orthopedic injuries. Individual results vary. Consult with a qualified physician to determine if this product is right for you. Contraindications, adverse reactions and precautions are available online at www.bioness.com
StimRouter™ and Bioness® are trademarks of Bioness Inc. | www.bioness.com | Rx Only
Additional information about StimRouter can be found at www.stimrouter.com.
Contacts
Media Contact:
for Bioness Inc.
Joel Behnke, 707-888-2617
